Truist Securities Downgrades Longboard Pharmaceuticals to Hold, Maintains Price Target to $60

Benzinga · 10/15 14:15
Truist Securities analyst Joon Lee downgrades Longboard Pharmaceuticals (NASDAQ:LBPH) from Buy to Hold and maintains the price target from $60 to $60.